It has been FDA-approved as Sprycel for use in the treatment of Acute lymphoblastic leukaemia and Chronic myelogenous leukaemia [200], and has been shown to inhibit nuclear localization and activity of YAP/TAZ in breast cancer cells as well as affect the viability of the latter [165]. Here, YAP1 is linked to breast carcinoma.